Management

Dr Reddy's Lab rises 2.3%

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters. - Dr Reddy"s to strengthen domestic biz - Dr Reddy"s plans to launch Lipitor"s generic version in US - Dr Reddy"s develops generic version of Pfizer"s Lipitor - Intermediate trend reversal confirmed - DRL net doubles to Rs 217 cr - Dr Reddy"s forays into transdermal patch segment The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of Nordic Bioscience said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
Wall Street ends in green; Indian ADRSs mixed
The Wall Street ended in positive territory on Wednesday. The Dow Jones moved up 61 points to 9,279. The Nasdaq added 13 points to 1,969.
Popular Articles

Wrong CPI
Sitaram Yechury, the CPI(M) leader, had a tongue-in-cheek explanation for Finance Minister Pranab Mukherjee ripping into Brinda Karat during the discussion on inflation in Parliament. According to Yechury, “The FM was talking about the Wholesale Price Index (WPI) but we were telling him to talk about the Consumer Price Index (CPI) which showed a sharp rise in food prices. As we mentioned CPI, he thought we were talking about the political outfit CPI. That might have angered him.”

Rajaratnam started firm with ex-McKinsey chief
Raj Rajaratnam, the billionaire hedge-fund manager accused of insider trading, started an investment firm in 2006 with partners including Rajat Gupta, former head of McKinsey & Co, and Mark Schwartz, ex-chairman of Goldman Sachs Group Inc’s Asia business.

© Copyright 2009